Fibroblast Growth Factor (FGF) Receptors

Sometimes, a dysregulation of Fibroblast Growth Factors (FGFs) may occur and causes cancer. The dysregulations usually fall into six categories: (1) a specific FGF ligand is overproduced; (2) the specificity of splice-variant FGFRs to endogenous FGF ligands have changed; (3) FGFRs are mutated, resulting in receptor dimerization or constitutive activation of the kinase; (4) there is a gene translocation in FGFRs that leads to over-expression or activation of the FGFR; (5) germline SNPs exist, which are related with increased risk of cancer; (6) the impairment of the normal attenuation and negative feedback. Considering this, it is no doubt that researchers are pursuing to generate agents to control FGF-ligand/receptor dysregulation.

Table 2. Current clinical development status of FGF/FGFR-targeting anticancer agents

Fibroblast Growth Factor & Receptor / Fibroblast Growth Factor (FGF) & Receptor Dysregulation in Cancer

Fibroblast Growth Factor (FGF) & Receptor Dysregulation in Cancer Related Studies

23000+ Products
cDNA Clones
Recombinant Cytokines
FGF Information
What is FGF
History of FGF & Receptor
Classification of FGF & Receptor
Mechanisms of FGF Action
Fibroblast Growth Factor (FGF) Receptors
FGF Signalling Pathway
FGF & Receptor Dysregulation in Cancer
FGF Inhibitor
FGF Reagents
FGF Proteins
FGF Antibodies
FGF cDNA Clones
All FGF Products
Growth Factor Family
Ephrin & Eph Receptor
EGF & Receptor
FGF & Receptor
Insulin-like Growth Factor System
Neurotrophin & Receptor
PDGF & Receptor
Receptor Tyrosine Kinase
R-Spondin Protein
VEGF & Receptor
Wnt Ligands & Receptors